Citi lowered the firm’s price target on Biogen (BIIB) to $190 from $215 and keeps a Neutral rating on the shares. The firm adjusted targets in the biopharma space as part of a Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target raised to $200 from $190 at Morgan Stanley
- Biogen price target lowered to $213 from $233 at RBC Capital
- Biogen expects Q1 results to include $34M expense on pre-tax basis
- Biogen price target raised to $237 from $228 at H.C. Wainwright
- Disney upgraded, Nike downgraded: Wall Street’s top analyst calls